Pemphigus vulgaris is a unique chronic condition of bullous autoimmune dermatosis whose development and diagnosis is mostly unidentifiable. It is classified as a specific hypersensitivity type II reaction that initiates the antibodies against the desmosomes, which are the maculae adherentes of the skin also known as the adhering spots in common term. These adhering spots keep the certain layers and compartments of the skin intact. When the desmosomes are invaded by the antibodies, the intact layers of the skin separate out and the clinical picture resembles a blister. With the passage of time the condition becomes worse and without treatment and monitoring the blister type lesions increase in size and surface area of the body similar to the condition of severe burn. The prime focus in the treatment of pemphigus vulgaris is to control the infirmity, prevent relapses, avoid adverse events and complications associated with the broad use of the steroids and immunosuppressive agents. Systemic corticosteroids evidenced as the golden standard in the treatment regimens of the pemphigus vulgaris. Azathioprine and mycophenolate mofetil are considered as the choice of drug in the treatment of the pemphigus vulgaris as a steroid sparing agent. Rituximab is believed to be immensely efficacious in unmanageable and refracted types of pemphigus vulgaris when other remedies fail to control the disease. One of the most noticeable complications of the pemphigus vulgaris is the compromised quality of life due to the blister forming all over the body which aggravates the soreness and pain on the affected area leading to ulceration and formation of erosive lesions. If there is a recurrence of the disease then the steroids doses will be checked properly and if needed then the doses could also be increased according to the weight in safe limit thus augmenting the immunosuppressants in the body and find an alternate safe drug in concomitant therapy